| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
In HaCaT cells, pretreatment with 1 μM astragaloside VI (AS-VI) boosted EGFR activation. The primary intestine metabolite of astragaloside IV, astragaloside VI, exhibits the highest activation of EGFR. It was projected that EGF would lead to 1.5 ± 0.03-fold increase in cell proliferation in positive control HaCaT cells as compared to the control. HaCaT and HDF cell proliferation can also be markedly enhanced by astragaloside VI at specific doses [1]. By triggering the EGFR/MAPK signaling cascade, astragaloside VI stimulates the growth of neural stem cells and improves neurological functional recovery following acute cerebral ischemia injury [2].
|
|---|---|
| ln Vivo |
Comparing Astragaloside VI to the control, wound healing was enhanced. Astragaloside VI shortened the time needed for wound closure in mice using a basic non-infected wound model by about 2-4 days as compared to the control group. When astragaloside VI was applied topically, pus output was lower than in the control group. Astragaloside VI-treated wounds healed more quickly than those in the petroleum jelly and control groups. Wounds treated with astragaloside VI were fully closed by day 22, however wounds treated with petroleum jelly and blank materials were not fully closed until day 26. A crucial stage in the development of granulation tissue and the healing of wounds is angiogenesis. In wound models that are both infected and non-infected, astragaloside VI promotes vascularization [1]. In the brain following temporary cerebral ischemia, astragaloside VI can efficiently activate the EGFR/MAPK signaling cascade, encourage the proliferation and neurogenesis of NSCs, and enhance the restoration of neurological function in rats following ischemic stroke [2].
|
| References |
|
| Additional Infomation |
Astragaloside VI has been reported in Astragalus mongholicus, Astragalus membranaceus, and Astragalus melanophrurius with data available.
|
| Molecular Formula |
C47H78O19
|
|---|---|
| Molecular Weight |
947.110820000001
|
| Exact Mass |
946.514
|
| CAS # |
84687-45-6
|
| PubChem CID |
71448940
|
| Appearance |
White to yellow solid powder
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
66
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O
|
| InChi Key |
FLPVEPQEIRRVKG-SXCMWBRFSA-N
|
| InChi Code |
InChI=1S/C47H78O19/c1-41(2)26(64-40-35(28(52)21(51)18-60-40)65-39-34(58)32(56)30(54)24(17-49)63-39)9-11-47-19-46(47)13-12-43(5)36(45(7)10-8-27(66-45)42(3,4)59)20(50)15-44(43,6)25(46)14-22(37(41)47)61-38-33(57)31(55)29(53)23(16-48)62-38/h20-40,48-59H,8-19H2,1-7H3/t20-,21+,22-,23+,24+,25-,26-,27-,28-,29+,30+,31-,32-,33+,34+,35+,36-,37-,38+,39-,40-,43+,44-,45+,46-,47+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-6-[(2S,3R,4S,5R)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~105.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0558 mL | 5.2792 mL | 10.5584 mL | |
| 5 mM | 0.2112 mL | 1.0558 mL | 2.1117 mL | |
| 10 mM | 0.1056 mL | 0.5279 mL | 1.0558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
